Bluejay Diagnostics shared its third-quarter results and announced big steps in its operations.

Nov 13, 2026, 4:10 PM ETResultsRead the original at SEC EDGAR

Good for BJDX

Bluejay finished SYMON-II enrollment above its planned 750-patient target and set up another cartridge-making site before a contract deadline. These steps support its planned FDA filing, but cash is expected to last only through Q2 2027 and more funding will be needed.

BJDX · Bluejay Diagnostics, Inc.

AI read · Good for BJDX

The AI's read

Completing enrollment and adding another cartridge-making site move the company closer to testing its product and preparing an FDA submission. Cash was $7.38 million at quarter-end, and operations used about $5.09 million over 9 months. The company expects cash to last through Q2 2027 and says more funding will be needed. The completed study and added supply option support progress, but the funding need limits how far the company can advance on its own.

Get alerts for BJDX

Follow Bluejay Diagnostics, Inc. (BJDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BJDX

Free on the App Store and Google Play, or on the web.